This is of interest because it suggests that therapies designed to selectively reduce Aβ plaques may only partly diminish the progression of neuropathology in AD brain and are particularly of note since 2P microscopy studies by Peters et al. (63) showed that tau is a driving force for Aβ plaque formation. This evidence concerns the gene MAPT and Alzheimer disease.